Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts

被引:0
作者
Emilie Normand
Anita Franco
Alain Moreau
Valérie Marcil
机构
[1] Research Center of the Sainte-Justine University Hospital,Department of Nutrition, Faculty of Medicine
[2] Université de Montreal,Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases
[3] Research Center of the Sainte-Justine University Hospital,Department of Biochemistry and Molecular Medicine, Faculty of Medicine
[4] Université de Montreal,Department of Stomatology, Faculty of Dentistry
[5] Université de Montréal,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
It has been proposed that girls with adolescent idiopathic scoliosis (AIS) tend to have a taller stature and a lower body mass index. Energy homeostasis, that is known to affect bone growth, could contribute to these characteristics. In circulation, dipeptidyl peptidase-4 (DPP-4) inactivates glucagon-like peptide-1 (GLP-1), an incretin that promotes insulin secretion and sensitivity. Our objectives were to investigate DPP-4 status in plasma and in osteoblasts of AIS subjects and controls and to evaluate the regulatory role of metabolic effectors on DPP-4 expression. DPP-4 activity was assessed in plasma of 113 girls and 62 age-matched controls. Osteoblasts were isolated from bone specimens of AIS patients and controls. Human cells were incubated with glucose, insulin, GLP-1 and butyrate. Gene and protein expressions were evaluated by RT-qPCR and Western blot. Our results showed 14% inferior plasma DPP-4 activity in AIS patients when compared to healthy controls (P = 0.0357). Similarly, osteoblasts derived from AIS subjects had lower DPP-4 gene and protein expression than controls by 90.5% and 57.1% respectively (P < 0.009). DPP-4 expression was regulated in a different manner in osteoblasts isolated from AIS participants compared to controls. Our results suggest a role for incretins in AIS development and severity.
引用
收藏
相关论文
共 50 条
[11]   Renal outcomes with dipeptidyl peptidase-4 inhibitors [J].
Scheen, A. J. ;
Delanaye, P. .
DIABETES & METABOLISM, 2018, 44 (02) :101-111
[12]   Cardiovascular effects of dipeptidyl peptidase-4 inhibitors [J].
Papagianni, M. ;
Tziomalos, K. .
HIPPOKRATIA, 2015, 19 (03) :195-199
[13]   Heart failure and dipeptidyl peptidase-4 inhibitors [J].
Krum, Henry ;
Skiba, Marina ;
Wu, Shiying ;
Hopper, Ingrid .
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (06) :603-607
[14]   The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors [J].
Kim, Na-Hyung ;
Yu, Taeyang ;
Lee, Dae Ho .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[15]   Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [J].
Shi, Sen ;
Koya, Daisuke ;
Kanasaki, Keizo .
FIBROGENESIS & TISSUE REPAIR, 2016, 9
[16]   Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review [J].
Richard, Kathleen R. ;
Shelburne, Jamie S. ;
Kirk, Julienne K. .
CLINICAL THERAPEUTICS, 2011, 33 (11) :1609-1629
[17]   Dipeptidyl peptidase-4 inhibitors and cardiovascular safety [J].
Davis, Timothy M. E. .
MEDICAL JOURNAL OF AUSTRALIA, 2014, 200 (08) :450-451
[18]   Pharmacology of Dipeptidyl Peptidase-4 InhibitorsSimilarities and Differences [J].
Roberta Baetta ;
Alberto Corsini .
Drugs, 2011, 71 :1441-1467
[19]   Nonglycemic effects of dipeptidyl peptidase-4 inhibitors [J].
Ametov, A. S. ;
Kamynina, L. L. .
TERAPEVTICHESKII ARKHIV, 2013, 85 (01) :98-102
[20]   Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [J].
Hong, Sangmo ;
Jung, Chang Hee ;
Han, Song ;
Park, Cheol-Young .
DIABETES & METABOLISM JOURNAL, 2022, 46 (01) :63-+